Formation of morphine from codeine in Chinese subjects of different CΥP2D6 genotypes

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 2, 1996, Pages 177-182

  Tseng, Chiung Yao ^a   Wang, Su Lan ^a   Lai, Ming Derg ^a   Lai, Ming Liang ^a   Huang, Jin Ding ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CODEINE; DRUG METABOLITE; MORPHINE; MORPHINE GLUCURONIDE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CHINESE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG URINE LEVEL; GENOTYPE; HETEROZYGOSITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; VOLUNTEER;

ADULT; ANALYSIS OF VARIANCE; ASIAN CONTINENTAL ANCESTRY GROUP; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CODEINE; CYTOCHROME P-450 CYP2D6; GENOTYPE; HUMANS; MALE; MORPHINE; POLYMERASE CHAIN REACTION; REFERENCE VALUES;

EID: 0029963641     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90133-2     Document Type: Article

References (27)

1. Sanfilippo G. Contributo sperimenteale all' ipotesidella smetilazione della codeine nellaorganismo; I: influenze della dose sull' assuefazione alla codeina. Boll Soc Ital Biol Sper 1948;24:723-6.
2. Dahlström B, Paalzow L. Pharmacokinetics and analgesia of codeine and its metabolite morphine. In: Elsevier/North-Holland, editor. Opiates and endogenous opioid peptides. Amsterdam: Biomedical Press, 1976, 395-8.
3. Adler TK, Fujimoto JM, Way EL, Baker EM. The metabolic fate of codeine in man. J Pharmacol Exp Ther 1955;114:251-62.
4. Chen ZR, Somogyi AA, Bochner F. Polymorphic O-demethylation of codeine. Lancet 1988;2:914-5.
5. Chen ZR, Somogyi AA, Reynolds G, Bochner F. Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. Br J Clin Pharmacol 1991;31:381-90.
6. Yue QY, Svenssen JO, Aim C, Sjöqvist F, Säwe J. Codeine O-demethylation cosegregates with polymorphic debrisoquine hydroxylation. Br J Clin Pharmacol 1989;28:639-45.
7. Yue QY, Svensson JO, Sjöqvist F, Säwe J. A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylation of debrisoquine. Br J Clin Pharmacol 1991;31:643-7.
8. Dayer P, Desmeules J, Leemann T, Striberni R. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P450 dbl-bufl). Biochem Biophys Res Commun 1988; 152:411-6.
9. Mortimer O, Persson K, Ladona MG, Spalding D, Zanger UM, Meyer UA, et al. Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of immunoidentified cytochrome P-450IID1. Clin Pharmacol Ther 1990;47:27-35.
10. Sindrup SH, Poulsen L, Brøsen K, Arendt-Nielsen L, Gram LF. Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers? Pain 1993;53:335-49.
11. Wang SL, Huang JD, Lai MD, Liu BH, Lai ML. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 1993;53:410-8.
12. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 1989;45:889-904.
13. Armstrong M, Fairbrother K, Idle JR, Daly AK. The cytochrome-P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population. Pharmacogenetics 1994;4:73-81.
14. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. J Biol Chem 1990;265:17209-14.
15. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994;46:452-9.
16. Lai ML, Wang SL, Lai MD, Lin ET, Tse M, Huang JD. Propranolol disposition in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1995;58:264-8.
17. Yue QY, Svensson JO, Sjöqvist F, Säwe J. Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylation of debrisoquine. Br J Clin Pharmacol 1991;31:635-42.
18. Desmeules J, Gascon MP, Dayer P, Magistris M. Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol 1991;41:23-6.
19. Cleary J, Mikus G, Somogyi A, Bochner F. The influence of pharmacogenetics on opioid analgesia: studies with codeine and oxycodone in the Spraque-Dawley/ Dark Agouti rat model. J Pharmacol Exp Ther 1994; 271:1528-34.
20. Yue QY, Svensson JO, Aim C, Sjöqvist F, Säwe J. Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. Br J Clin Pharmacol 1989;28:629-37.
21. Hanioka N, Kimura S, Meyer UA, Gonzalez FJ. The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934→A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition site. Am J Hum Genet 1990;47:994-1001.
22. Chen ZR, Bochner F, Somogyi A. Simultaneous determination of codeine, norcodeine and morphine in biological fluids by high performance liquid chromatography with fluorescence detection. J Chromatogr 1989;491:367-78.
23. Combie J, Blake JW, Nugent TE, Tobin T. Morphine glucuronide hydrolysis: superiority of β-glucuronidase from Patella Vulgata. Clin Chem 1982;28:83-6.
24. Johansen M, Rasmussen KE. Determination of pholcodine and its metabolites in urine by capillary gas chromatography. J Chromatogr 1990;532:277-84.
25. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D6 locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993;90: 11825-9.
26. Wang SL, Huang JD, Lai MD, Lai ML. R296C and other CYP2D6 mutations in Chinese. Pharmacogenetics 1995;5:385-8.
27. Heim MH, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990;336:529-32.